Why Are So Few HIV/AIDS Trials Conducted in Africa?

Article

People in sub-Saharan Africa carry the heaviest burden of HIV and AIDS, yet very few trials have been conducted on the African continent over the past two decades, say researchers in this weeks British Medical Journal.

This study confirms previous findings that HIV/AIDS trials are under-represented in sub-Saharan research and suggests that publication of trial results continues to be driven by researchers external to the continent.

The team identified and mapped all randomized controlled trials on HIV and AIDS conducted wholly or partly in Africa and reported before 2004. After extensive searching, they identified 77 trials published or reported from 1987 to 2003.

Most of the trials were funded by government agencies outside Africa, pharmaceutical companies and international non-government or inter-government organizations. Few principal investigators were based in African countries and there was no mention of ethical approval or informed consent in 19 and 17 trials, respectively.

The relatively small number of HIV/AIDS trials conducted in Africa is not commensurate with the burden of disease, say the authors. This may reflect a lack of economic ability, political will, or research capacity.

Geographical mapping as an adjunct to prospective trial registration is a useful tool for researchers and decision makers to track existing and future trials, they conclude.

Reference: Randomized controlled trials in Africa of HIV and AIDS: descriptive study and spatial distribution BMJ Volume 331, pp 742-6

Source: British Medical Journal

 

Recent Videos
Cameron Memorial Community Hospital series with ICT  (Image Credit: CMCH)
Cameron Memorial Community Hospital series with ICT (Image Credit: CMCH)
Cameron Memorial Community Hospital series with ICT (Image Credit: CMCH)
Cameron Memorial Community Hospital series with ICT (Image Credit: CMCH)
Isis Lamphier, MPH, MHA, CIC; Tori Whitacre Martonicz, MA; and Heather Stoltzfus, MPH, RN, CIC, at APIC Conference and Expo 2024 (Photo courtesy of Tori Whitacre Martonicz)
Lindsay K. Weir, MPH, CIC, Lead Infection Preventionist/Infection Preventionist III
•	Rebecca (Bartles) Crapanzano-Sigafoos, DrPH, MPH, CIC, FAPIC (corresponding author), executive director of APIC’s Center for Research, Practice, and Innovation, and lead author of the study.
Infection Control Today's Infection Intel: Staying Ahead With Company Updates and Product Innovations.
COVID-19 presentations at IDWeek in Las Angeles, California by Invivyd.   (Adobe Stock 333039083 by Production Perig)
Long COVID and Other Post-Viral Syndromes
Related Content